Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study

被引:50
作者
Barrios, V
Navarro, A
Esteras, A
Luque, M
Romero, J
Tamargo, J
Prieto, L
Carrasco, JL
Herranz, I
Navarro-Cid, J
Ruilope, LM
机构
[1] Hosp Ramon & Cajal, Serv Cardiol, ES-28034 Madrid, Spain
[2] Recordati Spain, Madrid, Spain
[3] Pharmazan Spain, Barcelona, Spain
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Univ Complutense, Sch Med, E-28040 Madrid, Spain
[6] Hosp 12 Octubre, E-28041 Madrid, Spain
关键词
arterial hypertension; calcium-channel blocker; daily clinical practice; dihydropyridine; Lercanidipine;
D O I
10.1080/08037050211265
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim: Lercanidipine, a long-acting dihydropyridine with a good antihypertensive efficacy and tolerability in clinical use. With the aim to determine the efficacy and tolerability of this drug in usual clinical practice we performed the ELYPSE trial. Methods: Grade 1 or 2 essential hypertensive patients in whom their physicians considered to prescribe a dihydropyridine were conferred to Lercanidipine 10 me, once daily with a 3-month follow-up; 9059 patients were included (age: 63 +/- 11 years; 58% women, 60% over 60 years, 56% grade 2 hypertensives and 69% previously treated with other antihypertensive drugs). A sub.-roup of 1267 patients (14%) who were included in the study had experienced adverse reactions with other drugs. Electronic case-report forms and a central database (Internet) were used in this trial. Results: At baseline, blood pressure (BP) was 160.1 +/- 10.2/95.6 +/- 6.6 mmHg; and heart rate (HR) 77.3 +/- 9.3 beats/min. Significant reductions in both systolic and diastolic BP were attained at 1 month with slight additional decreases 2 months later. At 3 months, BP was 141.4 +/- 11.3/83.1 +/- 6.9 mmHg, and HR 75.2 +/- 8.2 beats/min (p < 0.001 versus baseline). At the study end, 64% of the patients achieved a diastolic BP <90 mmHg, BP control (< 140/90 mmHg) was attained in 32%. In the subgroup of diabetics (n = 1269) an adequate BP control (< 130/85) was attained in only 16.4%. The overall incidence of adverse events was 6.5%, of which the most frequent were headache (2.9%), ankle oedema (1.2%), flushing (1.1%) and palpitations (0.6%). Withdrawal rate was < 1%. The efficacy and tolerability in the subgroup of patients included in the study due to adverse events with other drugs were similar to the whole study group. Conclusion: In this stud Lercanidipine has shown a good efficacy and toerability in daily clinical practice. Those findings are concordant with those reported in randomized controlled trials.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 30 条
[1]  
AMBROSIONI E, 1997, J CARDIOVASC PHAR S2, V29, pS16, DOI DOI 10.1097/00005344-199729002-00003
[2]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[3]   A comparison of observational studies and randomized, controlled trials. [J].
Benson, K ;
Hartz, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1878-1886
[4]  
CAFIERO M, 1997, J CARDIOVASC PHAR S2, V29, pS45
[5]  
CIRCO A, 1997, J CARDIOVASC PHAR S2, V29, pS22
[6]   Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892
[7]   Double-blind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension [J].
De Giorgio, LA ;
Orlandini, F ;
Malasoma, P ;
Zappa, A .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1999, 60 (10) :511-520
[8]   Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: A double-blind, randomized, parallel-group study [J].
Fogari, R ;
Malamani, GD ;
Zoppi, A ;
Preti, P ;
Vanasia, A ;
Fogari, E ;
Mugellini, A .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2000, 61 (12) :850-862
[9]  
GUARNERI L, 1997, J CARDIOVASC PHAR S1, V29, pS25
[10]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762